Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
NCT06220201

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Led by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Updated on 2026-02-10

120

Participants Needed

35

Research Sites

172 weeks

Total Duration

On this page

Sponsors

J

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Lead Sponsor

C

Celgene Corporation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

CONDITIONS

Official Title

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with relapsing forms of Multiple Sclerosis (RMS) with EDSS between 3.0 and 5.5
  • Diagnosed with relapsed/refractory MS or active secondary progressive MS with worsening disease in the past 12 months despite high-efficacy treatment for 6 months
  • Diagnosed with progressive forms of MS with EDSS between 3.0 and 6.0
  • Diagnosed with primary progressive MS that is treatment-resistant or inactive secondary progressive MS
  • Diagnosed with Myasthenia Gravis with MGFA classification II-IV at screening
  • Documented autoantibodies against AChR or MuSK
  • Refractory Myasthenia Gravis with disease activity on at least 2 immunosuppressants including steroids, NSIs, or biologics
  • Had thymectomy if indicated by current guidelines
Not Eligible

You will not qualify if you...

  • Unable to complete the 9-Hole Peg Test in at least one hand in under 240 seconds unless due to unrelated medical conditions
  • Unable to perform the Timed 25-Foot Walk Test in under 150 seconds
  • Presence of other neurological or muscle disorders affecting strength or causing weakness such as myositis, stroke, chronic inflammatory demyelinating polyradiculoneuropathy, Lambert-Eaton myasthenic syndrome
  • Other protocol-defined exclusion criteria apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 35 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

University of California, Irvine

Irvine, California, United States, 92697

Actively Recruiting

3

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

4

Colorado Blood Cancer Institute

Denver, Colorado, United States, 80218

Actively Recruiting

5

Yale-New Haven Hospital

New Haven, Connecticut, United States, 06510

Actively Recruiting

6

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

7

Local Institution - 0039

New Orleans, Louisiana, United States, 70121

Withdrawn

8

Local Institution - 0005

Boston, Massachusetts, United States, 02114

Completed

9

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

10

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

11

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

12

Neurological Institute of New York

New York, New York, United States, 10032

Actively Recruiting

13

University of Cincinnati Medical Center

Cincinnati, Ohio, United States, 45219

Actively Recruiting

14

Cleveland Clinic Mellen Center

Cleveland, Ohio, United States, 44195

Actively Recruiting

15

Oregon Health and Science University

Portland, Oregon, United States, 97239

Actively Recruiting

16

Swedish Medical Center

Seattle, Washington, United States, 98122

Actively Recruiting

17

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

18

Antwerp University Hospital

Edegem, Antwerpen, Belgium, 2650

Actively Recruiting

19

UZ Gent

Ghent, Oost-Vlaanderen, Belgium, 9000

Actively Recruiting

20

Hopital Claude Huriez - CHU de Lille

Lille, Nord, France, 59000

Actively Recruiting

21

Pitie Salpetriere University Hospital

Paris, Ville de Paris, France, 75013

Actively Recruiting

22

Universitaetsklinikum Essen

Essen, North Rhine-Westphalia, Germany, 45147

Actively Recruiting

23

Universitaetsklinikum Magdeburg

Magdeburg, Saxony-Anhalt, Germany, 39120

Actively Recruiting

24

Local Institution - 0033

Düsseldorf, Germany, 40225

Completed

25

Universitaetsklinikum Erlangen

Erlangen, Germany, 91054

Actively Recruiting

26

Klinikum der Universität München Großhadern

München, Germany, 81337

Actively Recruiting

27

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [Barcelona], Spain, 08035

Actively Recruiting

28

Local Institution - 0016

Barcelona, Barcelona [Barcelona], Spain, 08035

Not Yet Recruiting

29

Hospital Clínic de Barcelona

Barcelona, Catalunya [Cataluña], Spain, 08036

Actively Recruiting

30

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Comunidad de, Spain, 28034

Actively Recruiting

31

Hospital Universitari i Politecnic La Fe

Valencia, Spain, 46026

Actively Recruiting

32

Manchester Royal Infirmary

Manchester, Lancashire, United Kingdom, M20 2RZ

Actively Recruiting

33

University College London Hospital

London, London, City of, United Kingdom, NW1 2PG

Actively Recruiting

34

Salford Royal Hospital

Salford, Manchester, United Kingdom, M6 8HD

Actively Recruiting

35

Barts Health NHS Trust

London, United Kingdom, E1 1RD

Actively Recruiting

Loading map...

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

F

First line of the email MUST contain NCT # and Site #.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here